F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A
Haemophilia · 2025
DOI: 10.1111/hae.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Ming Y Lim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hemostasis and Thrombosis Research Society.
Abstract (Originalsprache)
Background
Neutralising antibodies (inhibitors) against factor VIII can result in severe bleeding in persons with nonsevere haemophilia A (NSHA). The INSIGHT study of 1112 persons with NSHA in a predominantly White population identified 19 different F8 missense variants that were associated with inhibitor development.
Objective
To describe the F8 variants and inhibitor development in persons with NSHA in a multiethnic cohort using the My Life, Our Future (MLOF) Research Repository and the American Thrombosis and Hemostasis Network dataset (ATHNdataset).
Methods
The MLOF Research Repository and ATHNdataset were queried for demographic, clinical and genotyping data.
Results
A total of 1805 persons with NSHA with at least one reportable F8 variant and known inhibitor status were included in this study. Inhibitors were developed in 142 (7.9%) persons with NSHA. Inhibitor development occurred in seventy F8 variants, of which the majority ( n = 67, 95.7%) were missense variants. These 70 F8 variants were identified in a total of 1006 (55.7%) persons with NSHA. Race or ethnicity was not associated with inhibitors in persons with NSHA.
Conclusion
The MLOF Research Repository identified additional F8 variants where inhibitor development occurred in a multiethnic cohort of NSHA. Identification of these F8 variants can inform both physicians and persons with NSHA to adopt measures to reduce the risk of inhibitor development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hematology and Hematologic Malignancies, Salt Lake City, Utah, USA.
- Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA.
- Department of Medicine, University of Washington, Seattle, Washington, USA.
- Institute For Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington, USA.
- Department of Medicine, Division of Hematology and Blood Research Center, University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Jill M Johnsen, Nigel S Key
Förderung
- Hemostasis and Thrombosis Research Society
Zitieren
APA
Lim, M. Y., Lee, K., Johnsen, J. M., & Key, N. S. (2025). F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A. Haemophilia. https://doi.org/10.1111/hae.70143
Vancouver
Lim MY, Lee K, Johnsen JM, Key NS. F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A. Haemophilia. 2025. doi:10.1111/hae.70143
BibTeX
@article{Lim2025,
author = {Lim, Ming Y and Lee, Kristy and Johnsen, Jill M and Key, Nigel S},
title = {F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.70143}
}
EUVIMED